Gallia Levy, MD, PhD, Associate Group Medical Director at Genentech, explains treatment options for hemophilia A.
Hemophilia A is a genetic disorder caused by missing or defective clotting protein, factor VIII. Symptoms are dependent on the level factor VIII present but in more severe cases, excessive bleeding can lead to severe pain, especially at joints.
Currently, most hemophilia A patients take a recombinant factor VIII product to control bleeding and numerous products are available, each with its own set of benefits and challenges.
Hemlibra (emicizumab-kxwh), a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis reduce bleeding episodes in persons with hemophilia A with or without factor VIII inhibitors.